Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations
Conditions: FGFR1 Gene Amplification; FGFR1 Gene Mutation; FGFR1 Gene Translocation; FGFR2 Gene Amplification; FGFR2 Gene Mutation; FGFR2 Gene Translocation; FGFR3 Gene Amplification; FGFR3 Gene Mutation; FGFR3 Gene Translocation; Metastatic Colorectal Carcinom a; Stage III Colorectal Cancer AJCC v8; Stage IIIA Colorectal Cancer AJCC v8; Stage IIIB Colorectal Cancer AJCC v8; Stage IIIC Colorectal Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8; Unresectable Colorectal Carcinoma Interventions: Drug: Pemigatinib; Other: Quality-of-Life Assessment Sponsors: Academic and Community Cancer Research United; National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials